Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review

Int J Neurosci. 2011 Sep;121(9):485-9. doi: 10.3109/00207454.2011.582240. Epub 2011 Jun 15.


Background: Bradykinesia has a significant impact on the lives of Parkinson's disease (PD) patients. Consequently, treating this symptom is of particular concern for patients and clinicians. A number of studies have documented the efficacy of rasagiline in reducing the severity of PD symptoms.

Objective: To summarize studies that specifically examined the impact of rasagiline on bradykinesia symptoms in PD patients across disease severity.

Methods: The EMBASE database was searched for relevant articles published between 2000 and November 2010.

Results: Three studies were identified that explicitly examined the effect of rasagiline on the bradykinesia subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination. In each, 1 mg/day rasagiline significantly reduced bradykinesia scores in patients.

Conclusion: As a monotherapy or an adjunctive therapy, rasagiline is an effective drug for reducing the severity of bradykinesia in PD patients.

Publication types

  • Review

MeSH terms

  • Databases, Factual / statistics & numerical data
  • Humans
  • Hypokinesia / drug therapy*
  • Hypokinesia / etiology*
  • Indans / therapeutic use*
  • Neuroprotective Agents / therapeutic use*
  • Parkinson Disease / complications*


  • Indans
  • Neuroprotective Agents
  • rasagiline